Provider review

NexLife Tirzepatide Review

What is the verdict on this provider?

NexLife advertises about $186 per month for tirzepatide, but whether mandatory fees are included is not confirmed in the captured source. Until fee inclusion is verified, that figure is not comparable with providers whose all-in cost is known.

What does tirzepatide actually cost at NexLife?

The captured source states: Injection: $215 month-to-month; $195/mo (3 mo, $585); $190/mo (6 mo, $1,140); $186/mo (12 mo, $2,232) Microdose: $189 monthly; $159.67/mo (3 mo, $479); $149.83/mo (6 mo, $899); $147/mo (12 mo, $1,764) ODT: $229 monthly; $219/mo (3 mo); $205/mo (6 mo); $199/mo (12 mo). Normalised, that is about $186 per month on the basis of complete published commitment ladder for the standard injection: medication included, no separate membership or shipping fee. Mandatory fees recorded: No separate membership fee; consultations and expedited shipping advertised as included.

The figure that matters for a treatment that continues for years is the recurring cost after any introductory period, including every mandatory fee. Advertised headline prices frequently exclude membership, consultation, or shipping charges, which is why this site normalises before comparing.

What does the captured source actually state?

How should the NexLife pricing structure be read?

NexLife publishes a monthly billing cadence in the captured source. Month-to-month billing generally costs more per month than a committed tier but leaves less money at risk if treatment is stopped early, which matters most before tolerance is established.

The same source also publishes semaglutide pricing, which is useful context: a provider pricing both drugs allows a switch without changing provider, though the two are not interchangeable and any change is a prescriber decision.

Source confidence is recorded as high because the figures come from Official provider rather than secondary reporting. That describes the capture, not how long it will remain accurate — pricing in this market changes frequently.

What has not been verified?

What should you confirm before enrolling?

• The recurring price after any introductory or first-month rate, in writing.
• Every mandatory fee: membership, consultation, shipping, and any dose-related surcharge.
• Which compounding pharmacy dispenses, its state licence number, and whether it is 503A or 503B.
• What happens to the price when your dose increases.
• The cancellation method, notice period, and whether prepaid months are refundable.
• Whether the plan auto-renews and how to stop it.
• That a licensed clinician reviews your intake and is reachable for side-effect questions.

What are the alternatives?

Primary source: NexLife pricing page · captured 2026-07-20. Eligibility and prescribing require clinician review. Verify checkout, dose/formulation, pharmacy, shipment cadence, and renewal terms.

What does this provider cost over two years?

What does NexLife charge across every program?

NexLife supplied its full pricing first-party. Every commitment tier below has been independently recomputed against the month-to-month rate.

What does each NexLife tirzepatide program cost?

Three tirzepatide programs are offered, and they are not interchangeable. Only the subcutaneous injection corresponds to the formulation studied in the SURMOUNT trials. The microdose and orally disintegrating tablet programs are different propositions with different evidence positions, set out below each table.

Tirzepatide — subcutaneous injection

Tirzepatide — microdose injection

Tirzepatide — orally disintegrating tablet (sublingual)

What does each NexLife semaglutide program cost?

Semaglutide is a different molecule and does not enter this site's tirzepatide rankings. The pricing is recorded because the relationship between a provider's semaglutide and tirzepatide rates is informative, and because readers frequently compare the two.

Do the published prices reconcile?

Every commitment tier was independently recomputed against the month-to-month rate. Sixteen of eighteen reconcile exactly. Two do not, and they are published here rather than quietly corrected, because a reader choosing one of those tiers would pay more than the advertised per-month rate implies.

Publishing these is not an accusation of bad faith. Pricing tables with several tiers and multiple products commonly develop arithmetic drift, and the two identified here have the character of clerical error rather than design. The reason they appear on this page is that the same reconciliation is applied to every provider, and suppressing a failed check for one would make the check meaningless everywhere.

What is NexLife's status after the compounding change?

NexLife was captured on 2026-07-20 advertising compounded tirzepatide. That capture predates nothing — it is recent — but the legal basis for the product it describes changed before it was taken. Compounding of tirzepatide was permitted only while the drug sat on the FDA shortage list. The shortage was declared resolved on 2 October 2024 and reaffirmed by declaratory order on 19 December 2024, and enforcement discretion ended on 18 February 2025 for 503A pharmacies and 19 March 2025 for 503B outsourcing facilities.

This site therefore treats NexLife's captured pricing as a dated historic record of what the compounded market charged, not as a live offer to compare against others. If NexLife continues to advertise compounded tirzepatide, the useful question is not whether the price is competitive but what legal basis the product is supplied under and which state-licensed pharmacy dispenses it. Neither is verified in this record.

How was NexLife's pricing classified?

Every provider on this site passes through the same four-part price test before it can appear in a cost ranking. The test asks whether the captured source states a recurring price, whether medication is included in that price, whether every mandatory fee is identified, and whether the figure describes the standard subcutaneous injection rather than an alternative formulation. NexLife is assessed below against each part in turn.

NexLife passes. The captured source states a recurring figure of $186 per month that includes medication and carries no separate mandatory membership charge, which is what makes it comparable with other providers on the same basis. That is less common in this market than it sounds: most captured sources advertise a starting price whose fee structure is left unstated, and those records cannot be placed on the same axis.

What would NexLife cost over time?

Because SURMOUNT-4 showed that stopping tirzepatide produces substantial weight regain, the financially relevant question is not what the first month costs but what sustained treatment costs. The table below projects NexLife's verified recurring rate across the horizons that maintenance actually implies. It assumes the price and the dose remain unchanged, neither of which is guaranteed — dose-coverage terms are unverified for this provider.

The committed tier saves $29 per month, or $348 over a year. That discount is real, but it is purchased with prepayment, and prepayment converts a clinical uncertainty into a financial one. Gastrointestinal effects cause a measurable share of discontinuation even in trials with structured support, so the relevant question before committing is what happens to the unused balance if treatment stops in month three. NexLife's cancellation and refund terms are unverified, which means that question cannot be answered from public information and must be asked directly.

How does NexLife compare with the providers that can be ranked?

NexLife sits at position 2 of 5 among providers whose all-in recurring cost is verifiable. The lowest verified rate in the dataset is TRYM Health at $125 per month; the highest is Eden at $298. NexLife is $61 per month above the lowest, which compounds to $732 over a year and $1,464 over two.

What else does NexLife's captured record contain?

The full record held for NexLife is reproduced below. This site publishes the underlying capture rather than only its own summary, so a reader can see exactly what the interpretation rests on and disagree with it if the reading looks wrong.

NexLife's semaglutide pricing is recorded because the relationship between a provider's semaglutide and tirzepatide pricing is informative on its own. Semaglutide is typically the cheaper of the two in this market, and a provider whose tirzepatide premium is unusually large or unusually small relative to its semaglutide rate is worth asking about — it can reflect different pharmacy sourcing, different dose coverage, or a promotional structure that will not persist. For NexLife the captured semaglutide text reads: Injection: $165 month-to-month; $149/mo (3 mo, $447); $147/mo (6 mo, $882); $145/mo (12 mo, $1,740) Microdose: $129 monthly; $117/mo (3 mo); $114/mo (6 mo); $110/mo (12 mo) ODT: $199 monthly; $177/mo (6 mo); $165/mo (12 mo)

The capture for NexLife is rated high confidence, meaning the figures were stated plainly on a first-party page in a form that left little room for interpretation. High confidence concerns the accuracy of the transcription, not the durability of the price: providers in this market change pricing frequently, and the verification date above is the honest boundary on how much weight the figure should carry.

What should you ask NexLife before enrolling?

These questions are selected against the specific gaps in NexLife's record rather than being a generic checklist. Ask them in writing and keep the reply: a verbal assurance from a sales channel is not a contractual term, and terms are what govern a dispute.

• What is the recurring monthly price after any introductory or first-month rate?
• What recurring fees apply on top of the medication, and are any of them waived initially?
• Which compounding pharmacy prepares the medication, and what is its state licence number?
• Is that pharmacy a 503A compounder or a 503B outsourcing facility?
• Does the price change when the dose increases to 10 mg or 15 mg?
• What concentration is dispensed, in mg/mL, and what beyond-use date is assigned?
• How is the plan cancelled, what notice is required, and are prepaid months refundable?
• Does the plan auto-renew, and how is renewal stopped?
• Which licensed clinician reviews the intake, and how are side-effect questions handled?

A provider that answers all of these in writing has demonstrated something meaningful about how it operates. A provider that will not name its compounding pharmacy before payment has also told you something, and it is worth weighing that refusal as evidence in its own right.

What would moving from NexLife to an approved product cost?

NexLife's captured recurring figure was $186 per month. Zepbound self-pay through the manufacturer's direct channel is $299 per month at the starting dose and $449 at maintenance doses of 7.5 mg and above. Moving from this provider's captured rate to the approved product would therefore represent an increase of about $113 per month at the starting dose and $263 per month at maintenance — roughly $3,156 over a year.

That increase is the honest cost of the regulatory change, and it is why an insurance route matters more now than provider comparison did before. A commercially insured reader with a covered weight-management benefit may pay a small copay rather than either figure above, which makes a coverage appeal the highest-value action available to most people in this position.

What should you ask NexLife now?

These questions are written for the post-shortage position rather than for a price comparison. The first three matter most: a provider still advertising compounded tirzepatide should be able to explain its legal basis and name its pharmacy, and an inability to do either is the most informative answer available.

• Is NexLife still supplying tirzepatide, and if so in what form?
• If a compounded product is still offered, what is the legal basis for supplying it?
• Which state-licensed pharmacy dispenses, and what is its licence number?
• Is the pharmacy a 503A compounder or a 503B outsourcing facility?
• Does the programme now offer FDA-approved Zepbound or Mounjaro instead?
• If an approved product is offered, is the price the medication alone or medication plus programme fees?
• Will the programme support an insurance prior-authorisation or appeal on your behalf?
• What happens to any prepaid balance if the programme can no longer supply what you paid for?
• How is cancellation handled, what notice is required, and are unused months refunded?
• Which licensed clinician is responsible for your care, and how are they contacted?

Prepaid balances deserve particular attention. Anyone who prepaid a multi-month compounded programme before the enforcement deadlines has a reasonable question about what they were supplied afterwards, and that question is worth putting in writing.

What do the technical terms on this page mean?

Definitions for the 10 technical terms this page uses, including 503A, 503B, GLP-1, auto-renewal — in the specific sense used above.

Sources for this page

• NexLife pricing page

Change history

Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.

What else is in this section?